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Knowledge, attitudes and practices regarding
hantavirus disease and willingness to
participate in a hantavirus vaccine trial in
southern Chile
F. Valdivieso ∗
Facultad de Medicina Clinica Alemana Universidad
del Desarrollo, Santiago, Chile
Background: Hantavirus disease (HD) in Chile is caused by
Andes virus with mortality rate of 35% and no speciﬁc treat-
ment. State-of-the-art research in hantavirus vaccines (HV) allow
envisioning candidate Andes vaccines in the near future. This vac-
cine/s will need Phase II evaluation in people at highest risk of
infection, such as rural inhabitants. We aimed to assess knowledge
of HD andwillingness to participate in a future HV trial in two rural
locations in southern Chile.
Methods & Materials: In Nov-Dec 2012, we performed a
cross-sectional oral survey inCurarrehue (39◦21‘S; 71◦34‘W;popu-
lation:7,706) and Corral (39◦49′S 73◦28′W; population:4,909). To a
random sample we applied a structured knowledge, attitudes and
practices questionnaire, regarding HD, vaccines and acceptability
to participate in a future HV trial.
Results: We interviewed 319 people from Corral and 321 from
Curarrehue, 62% female; 47% native Americans;mean age 50 years.
98% of subjects had heard about HD and 95% about the reservoir
“ratón colilargo”. 63% of women and 43% of men declared knowing
the symptoms of HD (p<0.000). 38% had adequate knowledge of
the mode of transmission of HD. 98% of the people perceived HD as
severe/very severe and 40% considered themselves or their families
at risk. 31% referred presence of rodents in their homes and 41% in
their storehouses. 75% trapped rodents without adequate precau-
tions. With regard to vaccines over 80% declared they help prevent
diseases and 93% would accept receiving a licensed HV. 58% of men
and 47% ofwomen (p=0.007)would participate in HV trial because
it is a beneﬁt and to prevent disease. Only 29% would accept their
children toparticipatewithhigher rejectionbetweenwomen.Main
reason for not participating is that a new vaccine is a risk.
Conclusion: Inhabitants of these locations have adequate
knowledge of the HD and of vaccines. They perceive themselves
at risk and fear HD and contact with rodents or droppings is fre-
quent. Acceptance of a licensed HV is high and nearly half would
participate in a HV trial. Further educational interventions may be
advisable to ensure informed voluntary consent for an HV trial.
http://dx.doi.org/10.1016/j.ijid.2014.03.1313
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Current status of pneumococcal protein
vaccines: A systematic review of literature
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1 Postgraduate Institute of Medical Education and
Research (PGIMER), Chandigarh, India
2 Post-graduate Institute of Medical Education and
Research, Chandigarh, India
Background: The various limitations with Pneumococcal con-
jugate vaccines (PCV) have prompted a relook at Pneumococcal
Protein Vaccines (PPV). A formal systematic review of literature
is therefore timely and relevant.
Objective:
Toundertake a systematic reviewof literature exploring the cur-
rent status of PCV in terms of efﬁcacy, safety, effectiveness, and
feasibility for use in public health programmes.
Methods & Materials: A systematic literature review was
undertaken through multiple databases using the term ‘pneumo-
coccal protein vaccine’. All citations were screened for relevance
using a three-step process, examining the Title, followed by
Abstract, followed by Full Text. There was no restriction in terms of
study design, language of publication and nature of report. The out-
comes of interest were: (i)Protein antigen under study, (ii)Status
of research, (iii)Data on efﬁcacy and safety data, and (iv)Data on
effectiveness and feasibility for use in a public health programme.
Results: Preliminary search yielded 1114 citations. Current lit-
erature identiﬁed four approaches to identify protein antigens
for PPV viz (i)Screening the pneumococcal genome for potential
surface protein candidates and/or homologues of known viru-
lence proteins, (ii)Anti-genomics i.e. screening the pneumococcal
peptide library with human sera, and/or transcriptional analy-
sis to identify upregulated genes, (iii)surface proteomics; and
(iv)exposure of the pneumococcal surface proteins by killing the
whole cell and stripping the capsule. These proteins could be
used in a vaccine as a (i)standalone vaccine, (ii)carrier in a PCV,
(iii)combination with PCV, and (iv)protein antigen-based vaccine.
Table 1 summarizes the current knowledge about various PPV.
The potential beneﬁts of PPV include the expectation of (i)covering
all serotypes of Pneumococcus, (ii)protection against various stages
of infection i.e carriage as well as disease, (iii)protection from
all types of infection including disease, pneumonia, otitis media;
(iv)easier and efﬁcient manufacturing; and (v)lower cost. The chal-
lenges with introduction into a public health programme are:
(i)Determination of correlates of protective efﬁcacy, (ii)Balancing
potential effectiveness of PPV against multiple serotypes versus
lower efﬁcacy against speciﬁc serotypes, and (iii)Development of a
Regulatory pathway for PPV.
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Table 1
Protein antigen Research data
Pneumococcal surface protein A (PspA) Protective aganist multiple pneumococcal
serotypes in mice models of invasive disease
pneumonia, and colonization. Vaccination of
healthy volunteers with PspA generated
antibodies aganist multiple strains that protected
mice aganist invasive disease. Human studies in
progess.
Pneumolysins.Pneumolysoids Protection aganist Pneuminia and increased
survival after intraperitoneal challenge. human
studies in progress
Neuraminidases (Nan) Protection aganist colonization and otitis media
Pneumococcal surface protein C (PspC) Protection aganist colonization. Protection aganist
sepsis
Pneumococcal protective protein A (PppA) Protection aganist lung infection. Protective
aganist nasopharyngeal colonization.
Pneumococcal Histidine Trial Protein D Protective aganist animal models of invasive
disease and pneumonia phase II trial reports
awaited.
IC4 antigens Protection aganist sepsis, pneumonia,
nasopharyngeal carriage.
Conclusion: Despite gaps in knowledge, Pneumococcal Protein
Vaccines could be an efﬁcacious, effective and economic alterna-
tive to currently available Pneumococcal Conjugate Vaccines for
the control of pneumococcal infections.
http://dx.doi.org/10.1016/j.ijid.2014.03.1314
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A survey of maternal pertussis vaccine uptake
in England
H. McAuslane1,∗, N. Andrews2, L. Coole1, A.
Wensley1
1 Public Health England, Leeds, United Kingdom
2 Public Health England, London, United Kingdom
Background: In 2012 the UK experienced a national outbreak
of pertussis. The highest rates of infections were seen in infants
aged less than 3months and therewere 14 deaths in this age group
attributable to pertussis. This outbreak prompted the Department
of Health (DH) to introduce a temporary vaccination programme
for pregnant women with the aim of preventing infections in very
young infants.
This survey aimed to estimate pertussis vaccine uptake in
pregnant women and describe variations according to age, ethnic-
ity, parity and location. Informationwas also gathered on inﬂuenza
vaccine uptake.
Methods & Materials: This was a cross–sectional survey of vac-
cine uptake amongwomendelivering inmaternity units in England
over a ﬁve-day period during April and May 2013. The target sam-
ple size was at least 380 women from maternity units throughout
the country. Units were asked to complete surveys alongside birth
paperwork for all women delivering a live birth during the 5 day
period. Proportions vaccinated were calculated with 95% conﬁ-
dence intervals and multiple logistic regression used to assess
differences in uptake.
Results: Twenty–nine trusts participated in the survey, retur-
ning 1325 surveys, 85% of which contained information about
vaccine uptake. Pertussis vaccine uptake was 52.6% (range 18.1%
to 72.4%). Inﬂuenza vaccine uptake was 52.2% (range 29.0% to
70.1%). Uptake of both vaccines was signiﬁcantly higher in the
White British ethnic group than in any other at 60% (95% CI 56%
- 62%). Women in the most deprived quintile were least likely to
have had either vaccine (pertussis vaccine OR v’s least deprived
0.44, 95%CI 0.28–0.67/inﬂuenza vaccineOR0.56, 95%CI 0.36–0.86).
Ninety–eight per cent of this sample received the pertussis vaccine
within the recommended 28–38 weeks gestation timeframe.
Conclusion: The results of this survey indicate that vaccine
uptake rates in pregnant women vary signiﬁcantly across regions
and are affected by factors such as ethnicity and deprivation.
Every opportunity should be taken to promote both pertussis and
inﬂuenza vaccines to pregnant women.
http://dx.doi.org/10.1016/j.ijid.2014.03.1315
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Reduction in vomiting associated with
norovirus vaccination in a live norovirus
human challenge study
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Background: Noroviruses (NoVs) are the leading cause of acute
infectious gastroenteritis worldwide and are highly contagious.
Although commonly associatedwith contaminated food andwater,
the majority of outbreaks reported in the United States are a result
of person-to-person transmission. Vomitingmay play a critical role
in person-to-person transmission. Since environmental contami-
nation resulting from episodes of vomiting have been implicated
in norovirus outbreaks, a strategy to reduce norovirus-associated
vomiting would have public health beneﬁt.
Methods & Materials: Healthy adult subjects age 18-49 were
randomized equally to two study groups to either receive two
intramuscular injected doses of an investigational norovirus biva-
lent GI.1/GII.4 VLP vaccine or saline placebo on study days 1 and
28. On study day 56, 109 subjects were admitted to an in-patient
unit and administered an oral dose of 4.4×103 PCR units of a live
GII.4 norovirus; 56 vaccine recipients and 53 saline placebo recipi-
